Clinical phenotypes related to smoking cessation

被引:1
作者
Minas, Markos [1 ]
Apostolidou, Eleni [1 ,2 ]
Goudouva, Irene [1 ]
Makris, Elias [1 ]
Gourgoulianis, Konstantinos I. [1 ]
Hatzoglou, Crissi [1 ,2 ]
机构
[1] Univ Thessaly Med Sch, Dept Resp Med, Larisa 41110, Biopolis, Greece
[2] Univ Thessaly Med Sch, Dept Physiol, Larisa 41110, Biopolis, Greece
关键词
Cluster analysis; Phenotypes; Smoking cessation; LUNG-FUNCTION; VARENICLINE; SMOKERS; PREDICTORS; BUPROPION; HEALTH; ASTHMA; NEUROBIOLOGY; COMPONENT; RELAPSE;
D O I
10.1016/j.jsat.2012.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: The aim of the current study is the identification of clinical phenotypes of patients visiting a specialized smoking cessation center and the determination of smoking cessation rate for each phenotype, 1 year after the initial evaluation. Methods: Seven hundred eighty-three smokers who visited the outpatient clinic were included in the study. Demographic data, smoking habits, tobacco dependence and comorbidities were recorded. Smoking cessation rates and carbon monoxide levels were determined 1 year after the initial evaluation. Results: The overall smoking cessation rate 1 year after the initial evaluation was 32.3%. Four distinct phenotypes were identified. The first one included mainly young women with low tobacco dependence and allergic profile. The second and the third ones included mainly men with high tobacco dependence, without comorbidities, treated with varenicline and bupropione SR, respectively. The fourth one included mainly older men with high tobacco dependence and smoking related comorbidities. Smoking cessation rates for each phenotype were 33.8, 39.4, 23.3, and 24.6%, respectively. Conclusion: Patients visiting a specialized smoking cessation center can be categorized in different phenotypes. Phenotyping may lead to a more personalized approach concerning smoking cessation. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 50 条
  • [21] Smoking cessation: Pharmacological strategies different from standard treatments
    Underner, M.
    Perriot, J.
    Peiffer, G.
    Harika-Germaneau, G.
    Jaafari, N.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2018, 74 (04) : 205 - 214
  • [22] Relapse Rate and Factors Related to Relapse in a 1-Year Follow-Up of Subjects Participating in a Smoking Cessation Program
    Kocak, Nagihan Durmus
    Eren, Aysegul
    Boga, Sibel
    Akturk, Ulku Aka
    Ozturk, Ulkem Angin
    Arinc, Sibel
    Sengul, Aysun
    RESPIRATORY CARE, 2015, 60 (12) : 1796 - 1803
  • [23] An update on the pharmacotherapeutic interventions for smoking cessation
    Barboza, Jose L.
    Patel, Radha
    Patel, Pooja
    Hudmon, Karen Suchanek
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (11) : 1483 - 1496
  • [24] Smoking cessation pharmacotherapy; varenicline or bupropion?
    Rahimi, Fatemeh
    Massoudifar, Ali
    Rahimi, Roya
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 32 (02) : 901 - 906
  • [26] Smoking Cessation Rate and Related Factors of Varenicline in Clinical Practice
    Song, Bitnoony
    Yun, Won-Suk
    Choi, Eun-Young
    Cheong, Yoo-Seock
    Park, Eal-Whan
    KOREAN JOURNAL OF FAMILY MEDICINE, 2011, 32 (02): : 112 - 119
  • [27] Smoking Cessation-Recent Advances
    McNeil, John J.
    Piccenna, Loretta
    Ioannides-Demos, Lisa L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (04) : 359 - 367
  • [28] Smoking cessation results in a clinical lung cancer screening program
    Kitts, Andrea K. Borondy
    McKee, Andrea B.
    Regis, Shawn M.
    Wald, Christoph
    Flacke, Sebastian
    McKee, Brady J.
    JOURNAL OF THORACIC DISEASE, 2016, 8 : S481 - S487
  • [29] Gender difference and effect of pharmacotherapy: findings from a smoking cessation service
    Walker, N. J.
    van Woerden, H. C.
    Kiparoglou, V.
    Yang, Y.
    Robinson, H.
    Croghan, E.
    BMC PUBLIC HEALTH, 2016, 16 : 1 - 8
  • [30] 'Real-world' effectiveness of smoking cessation treatments: a population study
    Kotz, Daniel
    Brown, Jamie
    West, Robert
    ADDICTION, 2014, 109 (03) : 491 - 499